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Abstract
Purpose There is no standardized surveillance protocol after intraductal papillary mucinous neoplasm (IPMN) resection. We 
report the findings of a large-scale survey in Japan, investigating the independent predictors of secondary invasive tumors 
by analyzing the epidemiology of secondary tumors of the remnant pancreas after initial IPMN resection.
Methods An institutional questionnaire about the remnant pancreas after pancreas resection was distributed at the 41st 
Annual Meeting of the Japanese Society of Pancreatic Surgery in Tokyo. We retrospectively analyzed the patient data includ-
ing pathological diagnosis, postoperative outcomes, and evaluation methods.
Results Redo pancreatectomy was performed for secondary disease in 213 (1.4%) of a total 15,777 patients. Eighty-eight of 
these 213 patients had undergone initial resection of IPMN. The types of secondary tumors after IPMN resection significantly 
depended on those of the primary tumors. Through short-interval and long-term follow-up, most of the secondary tumors 
were detected within 1–4 years. Logistic regression analysis revealed that the initial pathological diagnosis of invasive IPMN 
was an independent predictor of secondary invasive tumors in the remnant pancreas.
Conclusion Primary invasive IPMN proved to be a significant predictor of secondary invasive IPMN. Both short-interval 
and long-term follow-up may help to determine the prognosis of patients after IPMN resection.
Keywords Intraductal papillary mucinous neoplasm · Redo pancreatectomy · Secondary pancreatic remnant tumor
Introduction
The ability to detect intraductal papillary mucinous neo-
plasms (IPMNs) has improved with advances in high-quality 
diagnostic imaging, which enable the detailed evaluation 
of patients, post-resection of IPMN [1]. Surgical outcomes, 
including long-term survival after pancreatectomy, have also 
improved through surgical and pharmacological advances. 
Nonetheless, patients who have undergone pancreatic resec-
tion for IPMN may be at risk of a spectrum of conditions, 
ranging from benign non-invasive IPMN to invasive IPMN 
with a malignant invasive component, synchronous and 
metachronous multifocal tumor development in the pan-
creatic parenchyma, and the simultaneous development of 
pancreatic ductal adenocarcinoma (PDAC) [2–5]. In 2013, 
European experts issued consensus statements about post-
operative IPMN surveillance [6], and in 2012 and 2015, the 
International Association of Pancreatology (IAP) and the 
American Gastroenterological Association (AGA), respec-
tively, published guidelines for the management of IPMN 
patients [7, 8]. The international guidelines from the IAP 
were subsequently revised in 2017 [9]. Nonetheless, the 
level of evidence within these reports is fragmentary due 
to the lack of large-scale cohort studies on the occurrence 
and recurrence of secondary tumors after IPMN resec-
tion. Although retrospective studies have been conducted 
on secondary tumors after IPMN resection, which support 
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the above guidelines and statements, they are limited by the 
low number of cases of recurrence [10–12]. Thus, further 
investigations are necessary to establish a standardized post-
operative follow-up protocol for patients who have under-
gone IPMN resection. This can be improved by detailed data 
accumulation and analysis of the limited diseases in this 
field.
Several studies have demonstrated favorable outcomes 
after repeated resection of pancreatic remnants for second-
ary tumors including recurrent IPMN [10, 13, 14] and PDAC 
[15–17]. Unfortunately, in Japan, there is a limited database 
for the analysis of secondary tumors after IPMN resection, 
and no established postoperative protocol. We report the 
findings of our nationwide investigation based on an insti-
tutional questionnaire distributed at the 41st Annual Meet-
ing of the Japanese Society of Pancreatic Surgery (JSPS), 
regarding the independent predictors of secondary invasive 
tumors through an analysis of the epidemiological and 
pathological features of secondary tumors of the remnant 
pancreas after initial resection of IPMN.
Materials and methods
Study design
We distributed an institutional questionnaire about the 
remnant pancreas after IPMN resection at the 41st Annual 
Meeting of the JSPS in Tokyo, in 2014. We defined “redo 
pancreatectomy” as repeat resection for a secondary tumor 
in the remnant pancreas after initial pancreatectomy. The 
questionnaire consisted of several questions about the num-
ber of pancreatectomies, the surveillance system for the pan-
creatic remnant after the initial pancreatectomy, and cases of 
redo pancreatectomy between January, 2009 and December, 
2013. Responses were collected from 91 institutions affili-
ated with the JSPS. The question of surveillance after the 
initial pancreatectomy included an interval of evaluation, a 
follow-up period, and imaging modalities such as computed 
tomography and magnetic resonance imaging. Patients were 
excluded if written informed consent was not obtained or if 
they had undergone the initial pancreatectomy for tumors 
other than IPMN. This study protocol was approved by the 
ethics committee of Tokyo Dental Collage Ichikawa General 
Hospital (#I14-12, May 02, 2014).
Study variables
Patient characteristics, the initial surgical procedure, patho-
logical diagnosis at the initial surgery, and postoperative 
outcomes including complications such as pancreatitis, dia-
betes mellitus (new onset or worse) or dilatation of the main 
pancreatic duct (MPD)  (> 2 mm larger in diameter than the 
preoperative measurement), secondary surgical procedure, 
and pathological diagnosis at redo pancreatectomy, were 
collected. We focused not only on the number and timing of 
secondary tumors such as non-invasive/invasive IPMN and 
PDAC, but also on the relationship between the primary and 
secondary tumors.
Statistical analysis
To identify the independent predictors of invasive IPMN 
or PDAC, the predictive dependent variables found to be 
significant in univariate and multivariate analyses were 
analyzed by logistic regression analysis. After univariate 
logistic regression analysis of 11 predictive dependent vari-
ables, those variables found to be significant or to show a 
trend toward being an independent predictor were analyzed 
by multivariate logistic regression analysis. Differences 
in timing of the development of each tumor (non-invasive 
IPMN, invasive IPMN, and PDAC) were analyzed by the 
Kruskal–Wallis test. A p value < 0.05 was considered signifi-
cant. All statistical analyses were carried out by JMP 15.1 
for Windows (SAS Institute, Cary, NC, USA).
Results
Initial postoperative characteristics
A total of 15,777 pancreatectomies performed at 91 institu-
tions in Japan were recorded between 2009 and 2013. Redo 
pancreatectomy was performed for secondary disease in 
213 (1.4%) of these patients. Written informed consent was 
obtained from all but one patient. We analyzed, retrospec-
tively, 88 redo pancreatectomy patients who underwent the 
initial resection for IPMN. Table 1 summarizes the baseline 
characteristics of these 88 patients (56 men and 32 women; 
average age, 67.5 ± 7.3 years; range, 54–88 years). The ini-
tial pathological diagnosis was non-invasive IPMN in 51 
patients and invasive IPMN in 37 patients. Complications 
after the initial operation included main pancreatic duct 
dilatation (n = 53, 60.2%), postoperative pancreatitis (n = 8, 
9.1%), and new-onset or worsening diabetes (n = 55, 62.5%).
Pathological assessment between the primary 
and secondary tumors
The secondary pancreatic remnant tumors that developed 
in the 51 patients with non-invasive IPMN at the time of 
initial IPMN resection were non-invasive IPMN (n = 26, 
51.0%), invasive IPMN (n = 12, 23.5%) and PDAC (n = 9, 
17.6%), whereas the secondary pancreatic remnant tumors 
that developed in the 37 patients with invasive IPMN at the 
time of the initial IPMN resection were non-invasive IPMN 
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(n = 6, 16.2%), invasive IPMN (n = 25, 67.6%) and PDAC 
(n = 6, 16.2%) (Fig. 1). Table 2 summarizes the characteris-
tics of the patients who underwent redo pancreatectomy after 
the initial IPMN resection. A median period of 37.0 months 
(range 1–179 months) after the initial IPMN resection, total 
pancreatectomy and partial resection for secondary tumors 
were performed in 75 patients (85.2%) and 13 patients 
(14.8%), respectively. No residual tumors after redo pan-
createctomy (R0) were identified in 85 patients (96.6%). 
Timing of secondary tumor development 
in the remnant pancreas
The follow-up interval of surveillance for the remnant pan-
creas after the initial resection was every 3–4 months in 
67 institutions (73.6%) and every 6 months in 19 institu-
tions (20.9%). The total follow-up times of surveillance 
were over 5 years in 61 institutions (67.0%) and 5 years in 
22 institutions (24.2%). All 91 institutions used computed 
tomography (CT) as the imaging modality for surveillance, 
43 institutions (47.3%) also used magnetic resonance 
imaging (MRI) and/or magnetic resonance cholangiopan-
creatography, and 17 institutions (18.7%) used ultrasonog-
raphy. Additionally, 7 (7.7%) and 3 (3.3%) institutions 
used endoscopic ultrasonography (EUS) and endoscopic 
retrograde cholangiopancreatography, respectively.
A histogram of secondary tumor development dem-
onstrated that most secondary tumors occurred within 
1–4 years (Fig. 2a). Secondary tumors developed within 
5 years and between 5 and 15 years, in 65 (73.9%) and 23 
(26.1%) patients, respectively. A histogram of the number 
of secondary non-invasive and invasive IPMN and PDAC 
Table 1  Patients’ characteristics at the initial pancreatectomy
IPMN intraductal papillary mucinous neoplasm, SD standard devia-
tion
n = 88
Age, years, mean (± SD) 67.5 (± 7.3)
Male gender, n (%) 56 (63.6)
Location of the tumor, n (%)
 Pancreatic head 31 (35.2)
 Pancreatic body/tail 57 (64.8)




Pathology of the primary tumor, n (%)
 Non-invasive IPMN 51 (58.0)
 Invasive IPMN 37 (42.0)
Residual disease in the remnant pancreas, n (%)
 IPMN 30 (34.1)
 Positive margin 5 (5.7)
 None 50 (56.8)
 Unknown 3 (3.4)
Fig. 1  Pathological findings 
of the primary and secondary 
tumors. IPMN intraductal papil-




















(17.6%) (23.5%) (51.0%) (7.8%)
(16.2%) (67.6%) (16.2%)
Non-  
Table 2  Redo-pancreatectomy




 Total remnant pancreatectomy 75 (85.2)
 Partial resection 13 (14.8)
Second pathology, n (%)
 IPMN 69 (78.4)
  Non-invasive IPMN 32 (46.4)
  Invasive IPMN 37 (53.6)
 PDAC 15 (17.0)
 Other 4 (4.5)
Residual tumor, n (%)
 R0 85 (96.6)
 R1/2 3 (3.4)
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tumors showed no significant difference in the timing of 
secondary tumor development in the remnant pancreas 
(p = 0.335, Fig. 2b).
Predictors of invasive IPMN development 
in the remnant pancreas
Univariate logistic regression analysis of the 11 variables 
revealed a significant difference only in the initial patho-
logical diagnosis of invasive IPMN (p < 0.001, odds ratio 
6.60, 95% CI 2.56–16.99; Table 3) and that the absence of 
pancreatitis had a high odds ratio with a trend toward being 
an independent predictor (p = 0.106, odds ratio 5.86, 95% 
CI 0.69–48.89; Table 3). Multivariate logistic regression 
analysis of these variables revealed that the initial patho-
logical diagnosis of invasive IPMN was an independent pre-
dictor of secondary invasive IPMN in the remnant pancreas 
(p = 0.001, odds ratio 5.28, 95% CI 1.95–14.30; Table 3). No 
significant predictors for the development of PDAC in the 
remnant pancreas were identified (Table 3).
Discussion
Several studies on recurrent secondary IPMN and metachro-
nous PDAC after IPMN resection have been reported 
(Table 4). While the number of target patients was higher 
in previous studies than in the present study, analyzing the 
developmental patterns of secondary tumors was challenging 
because of the low number of cases of redo pancreatectomy. 
The incidence of redo pancreatectomy for secondary tumors 
after initial resection for IPMN was reported as 1.4–8.5% 
(median 3.3%) and the actual numbers of redo pancrea-
tectomy reported previously ranged from 3–36 (Table 4). 
Hence, we tried to identify the independent predictors of 
secondary invasive tumors by analyzing the epidemiology 
and pathological features of secondary tumors of the rem-
nant pancreas after the initial resection of IPMN in 88 redo 
pancreatectomy cases for IPMN from a large-scale survey 
of institutions all over Japan.
There are limited data on appropriate surveillance 
strategies for the remnant pancreas after IPMN resection. 
Moreover, the following three guidelines have different 
postoperative follow-up methods, potentially overlooking 
the early recurrence of secondary tumors. For instance, 
the Revision of the International Consensus Guidelines for 
the Management of IPMN from the IAP in 2017 recom-
mended postoperative surveillance by CT and CA19-9 levels 
Fig. 2  Timing of secondary 
tumor development in the 
remnant pancreas (a) and the 
breakdown of secondary tumors 
(b). IPMN intraductal papillary 
mucinous neoplasm, PDAC 
pancreatic ductal adenocarci-
noma
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within 6–12 months for non-invasive IPMN. In particular, 
the guidelines recommended performing a cross-sectional 
imaging modality at least every 6 months for patients with 
either a family history of PDAC, a positive surgical margin 
with high-grade dysplasia (HGD) in the remnant pancreas, 
or non-intestinal pathological subtypes of resected IPMN 
[9]. Conversely, the 2013 European expert consensus state-
ment recommended annual postoperative follow-up with 
MRI or EUS for non-invasive IPMN and compliance with 
the guidelines for PDAC for invasive IPMN [6]. The 2015 
AGA guidelines suggested that periodic surveillance was 
not required for low-grade dysplasia in cystic tumors, but 
Table 3  Univariate and multivariate analyses of predictors of secondary invasive intraductal papillary mucinous neoplasm and pancreatic ductal 
adenocarcinoma in the remnant pancreas
CI confidence interval, IPMN intraductal papillary mucinous neoplasm, MPD main pancreatic duct, PDAC pancreatic ductal adenocarcinoma
Variables Secondary invasive IPMN Secondary PDAC
Univariate analysis Multivariate analysis Univariate analysis
p value Odds ratio (95% CI) p value Odds ratio (95% CI) p value Odds ratio (95% CI)
Age 0.948 1.00 (0.94–1.06) 0.055 1.09 (1.00–1.18)
Gender
 Female vs male 0.130 1.98 (0.81–4.81) 0.761 0.83 (0.26–2.70)
Location of tumor
 Head vs body-tail 0.934 0.96 (0.40–2.34) 0.122 2.43 (0.79–7.53)
Residual tumor
 Absent vs present 0.888 1.14 (0.18–7.20) 0.641 102.93 ( -  -  - )
Cut end positive
 Absent vs present 0.906 1.12 (0.18–7.05) 0.636 110.28 ( -  -  - )
Pathology of the primary tumor
 Invasive IPMN vs non-
invasive IPMN
 < 0.001 6.60 (2.56–16.99) 0.001 5.28 (1.95–14.30) 0.828 0.88 (0.28–2.74)
Residual IPMN
 Present vs absent 0.729 1.17 (0.48–2.88) 0.204 2.40 (0.62–9.28)
Complications
 Absent vs present 0.148 2.13 (0.76–5.96) 0.506 0.66 (0.20–2.24)
Dilatation of MPD
 Absent vs present 0.897 1.06 (0.44–2.58) 0.453 1.54 (0.50–4.75)
Pancreatitis
 Absent vs present 0.106 5.86 (0.69–48.89) 0.091 6.95 (0.74–65.60) 0.128 0.30 (0.06–1.42)
Diabetes
 Absent vs present 0.666 1.21 (0.51–2.91) 0.856 1.11 (0.36–3.47)
Table 4  Reports of cases of recurrence in the remnant pancreas and redo-pancreatectomy
IPMN intraductal papillary mucinous neoplasm, PDAC pancreatic ductal adenocarcinoma, PTX pancreatectomy




















He [10] 2013 130 100: 0 22 (16.9%) 46 11 (8.5%) 3 (27%)
Kang [11] 2014 366 81: 19 24 (6.6%) 40 5 (1.4%) 4 (80%) 1 (20%)
Yogi [20] 2015 153 77: 23 10 (6.5%) 43 6 (3.9%) 3 (50%)
Marchgiani [23] 2015 381 78: 22 36 (9.4%) 52 9 (2.4%) 7 (78%)
Miyasaka [24] 2016 195 82: 18 13 (6.7%) 45 10 (5.1%) 4 (40%) 4 (40%)
Hirono [18] 2016 257 67: 33 14 (5.5%) 36 8 (3.1%) 2 (25%) 2 (25%)
Blackham [19] 2017 100 100: 0 9 (9.0%) 15 3 (3.0%)
Hirono [14] 2020 1074 77:23 70 (6.5%) 40 36 (3.4%) 16 (44%) 8 (22%)
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that follow-up with MRI should be done every 2 years for 
HGD or invasive cancer in cystic tumors [7]. Our study 
showed that approximately 70% of the institutions surveyed 
performed postoperative follow-up with CT and MRI every 
3–4 months. This detailed and precise follow-up detected 
the secondary tumors in our study, and most of the second-
ary malignant or potentially malignant tumors were resected 
within 1–4 years in the institute of JSPS. Although further 
evidence is necessary, our data suggest that postoperative 
follow-up at least every 3–4 months could lead to the early 
detection of recurrence, which may be reflected in the prog-
nosis of patients after IPMN resection.
In addition to short-term postoperative evaluation for the 
early detection of recurrence, long-term follow-up for late-
onset secondary tumor development was required. Our study 
showed a median period of 37 months for secondary tumor 
detection, which was almost equivalent to 15–52 months in 
previous studies, as shown in Table 4. Moreover, 26.1% of 
the patients suffered relapse with secondary tumors, more 
than 5 years after initial IPMN resection. Secondary inva-
sive IPMN tended to develop later than other tumors, after 
median periods of 40 months for invasive IPMN, 32 months 
for non-invasive IPMN, and 26 months for PDAC. Several 
other reports have demonstrated the importance of long-term 
surveillance for patients with secondary tumors more than 
5 years after initial IPMN resection [5, 14, 18]. After non-
invasive IPMN resection, the cumulative risk of a secondary 
tumor requiring surgery at 1, 5, and 10 years was 1.6%, 14%, 
and 18%, respectively [10]. Combined with this evidence, 
our data support periodic and long-term follow-up after the 
initial pancreatectomy. In addition to intrapancreatic recur-
rence during follow-up, the possibility of extrapancreatic 
recurrence should also be considered. Extrapancreatic recur-
rence from non-invasive IPMN is thought to be rare [10, 
11, 14, 19–22], although metastatic recurrence of invasive 
IPMN to extrapancreatic organs was reported at a high rate 
of 45–57% [20, 23]. Thus, a protocol for long-term postop-
erative surveillance is required so as not to miss any recur-
rence after IPMN resection because the risk of intra- and 
extrapancreatic recurrence increases year by year.
There is limited evidence about whether secondary 
tumors in the remnant pancreas after IPMN resection recur 
like the primary tumor. The fact that secondary IPMN devel-
oped in the remnant pancreas after primary IPMN resection 
in 78.4% of the patients in this series suggests that secondary 
tumors after IPMN resection tend to be similar to the pri-
mary tumors (Table 2). Moreover, secondary non-invasive 
IPMNs developed in 51.0% of patients with primary non-
invasive IPMNs, whereas secondary invasive IPMNs devel-
oped in 67.6% of the patients with primary invasive IPMNs 
(Fig. 1), suggesting that primary tumors may be a high pre-
dictor of the development of a similar secondary tumor.
Several independent predictors for a secondary tumor in 
the remnant pancreas after resection of initial IPMN have 
been reported, based on analyses of initial IPMN patients. 
These predictors include preoperative symptoms, tumor 
location (body/tail), MPD dilatation (> 10 mm) or HGD/
invasive IPMN at the initial resection [14, 24]. These studies 
were valuable for the collection and detailed analysis of data 
on more patients who underwent pancreatectomy for initial 
IPMN. However, there were only 36 and 10 cases of redo 
pancreatectomy, respectively, in these studies (Table 4). Our 
study is unique, because it analyzed independent predictors 
in 88 patients who underwent redo pancreatectomy for a 
secondary tumor in the remnant pancreas after resection of 
initial IPMN, from a nationwide survey. Consistent with pre-
vious studies on independent predictors of secondary tumor 
development, only primary invasive IPMN at the initial 
resection was identified as a significant predictor (Table 3).
According to a recent study on metachronous secondary 
tumors after IPMN resection using targeted DNA sequenc-
ing, secondary tumors independent of the primary IPMN 
developed in more than half of the patients [25]. A more 
detailed subdivision of pathological evaluation of the pri-
mary tumors may enable us to identify a causal relationship 
between the primary tumor and secondary tumor types. In 
light of these findings, the types of secondary tumor after 
IPMN resection may be highly dependent on those of the 
primary tumor. This highlights the necessity for continued 
postoperative assessment of secondary tumor development 
in the remnant pancreas after IPMN resection.
It is noteworthy that the incidence of PDAC occurring 
as the secondary tumor after IPMN resection was 16–17% 
in the present study. A previous study similarly found the 
5-year and 10-year cumulative incidences of PDAC in the 
remnant pancreas after IPMN resection to be 4.5% and 5.9%, 
respectively [24]. Surprisingly, we found that the PDAC 
generally developed within 5 years, although our logistic 
regression analysis could not specify a significant predictor 
of PDAC development (Table 3). However, it has been sug-
gested that all patients who have undergone IPMN resection 
have high probability of PDAC development and that IPMN 
itself is a significant risk factor for PDAC development.
This study had some limitations. Although we collected 
recorded cases of patients who had undergone IPMN resec-
tion in the study period, through questionnaires from all over 
Japan, the number of subjects analyzed was not considerably 
high (88 patients). Furthermore, several clinicopathological 
data such as the morphologic type of IPMN, pathological 
grade of dysplasia, and size of tumor were not included in 
this study. Patients whose secondary tumor was not resected 
after initial IPMN resection were also not included. An 
increased dataset from future questionnaires will add to this 
model and allow for further investigation.
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Conclusion
In summary, we conducted a nationwide large-scale survey 
in Japan of patients who underwent redo pancreatectomy for 
secondary tumor development in the remnant pancreas after 
initial IPMN resection. The types of secondary tumors after 
IPMN resection correlated with those of the primary tumors, 
and only primary invasive IPMN was revealed to be a sig-
nificant predictor of secondary invasive IPMN. Both short-
interval and maximally long-term postoperative follow-up 
will reflect the prognosis of patients after IPMN resection. 
Subsequent research investigating the correlation between 
the primary and the secondary tumor, and the most effective 
follow-up method, must include prospective studies.
Acknowledgement We thank all of the JSPS surgeons at the 91 prin-
cipal institutes, who kindly participated in the study (Appendix 1). 
We also thank the support staff of the institutions that aided the work 
of the JSPS. We are grateful to Dr. Masateru Uchiyama, M.D., Ph.D., 
Mr. Kento Kawai, MSc, and Dr. Masanori Niimi, M.D., Ph.D., for their 
editorial assistance.
Funding None.
Compliance with ethical standards 
Conflict of interest We have no conflicts of interest to disclose as de-
scribed by Surgery Today.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
Appendix 1
Supporting information: participating 
institutions
Department of Surgery and Oncology, Graduate school 
of medical sciences, Kyushu University; Department of 
Surgery, Institute of Gastroenterology, Tokyo Women’s 
Medical University Hospital, Department of Hepatobiliary-
Pancreatic Surgery, National Cancer Center Hospital East; 
Department of Surgery, Tohoku University Graduate School 
of Medicine, Department of Surgery, Institute of Biomedi-
cal and Health Science, Hiroshima University; Department 
of General Surgery, Graduate School of Medicine, Chiba 
University; Department of Gastroenterological Surgery, 
Nagoya University Graduate School of Medicine; Division 
of Digestive and General Surgery, Niigata University Gradu-
ate, School of Medical and Dental Sciences; Department 
of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, 
Kobe University Graduate School of Medicine; Department 
of Surgery, Saitama Medical University International Medi-
cal Center; Department of Surgery, Iwate Medical University 
School of Medicine; Department of Surgery, Kansai Medi-
cal University; Department of Surgery, Surgical Oncology 
and Science, Sapporo Medical University; Department of 
Surgery, Jichi Medical University; Department of Hepatobil-
iary and Pancreatic Surgery, Chiba Cancer Center; Depart-
ment of Surgery, Nagasaki University Graduate School of 
Biomedical Sciences; Department of General Surgery and 
Pancreatic Surgery, Fujita Health University; Hepatobil-
iary-Pancreatic and Transplant Surgery, Mie University 
Graduate School of Medicine; Department of Surgery, Asa-
hikawa Medical University; Department of Hepato-Biliary-
Pancreatic and Breast Surgery, Ehime University Graduate 
School of Medicine; Department of Surgery, Oita Red Cross 
Hospital; Department of General and Gastroenterological 
Surgery, Osaka Medical College; Department of Gastroen-
terological Surgery, Graduate School of Medicine, Osaka 
University; Department of Digestive Surgery, Kawasaki 
Medical School; Division of Hepatobiliary and Pancreatic 
Surgery, Department of Surgery, Kurume University School 
of Medicine; Department of Surgery, Sapporo Kosei Hospi-
tal; Department of Digestive Surgery, Tenriyorodusoudanjyo 
Hospital; Department of Surgery, Nara Medical University; 
Division of Hepato-Biliary-Pancreas and Digestive Surgery 
in the Department of Surgery, University of Miyazaki, Fac-
ulty of Medicine; First Department of Surgery, Graduate 
School of Medical Science, Yamagata University; Depart-
ment of Gastroenterological Surgery, Yokohama City Uni-
versity Graduate School of Medicine; Second Department 
of Surgery, Wakayama Medical University; Department 
of Surgery, Showa Inan General Hospital; Department of 
Gastroenterological Surgery, Kanazawa University Hos-
pital; Department of Surgery, Kitasato University School 
of Medicine; Department of Surgery, Kyorin University 
School of Medicine; Department of Gastroenterological 
and General Surgery, St. Marianna University, School of 
Medicine; Department of Surgery, Chiba Rosai Hospital; 
Department of Hepatobiliary and Pancreatic Surgery, Gradu-
ate School of Medicine, Tokyo Medical and Dental Uni-
versity; Department of Hepato-Biliary-Pancreatic Surgery, 
Tochigi Cancer Center; Department of Surgery and Science, 
Graduate School of Medicine and Pharmaceutical Sciences, 
Toyama University; Department of Surgery, Hyogo College 
1679Surgery Today (2020) 50:1672–1680 
1 3
of Medicine; Department of Gastroenterological Surgery, 
Fukuyama City Hospital; Department of Surgery, Meiwa 
Hospital; Department of Surgery, Ashikaga Red Cross Hos-
pital; Department of Surgery, Ibaraki Prefectural Central 
Hospital; Department of Gastroenterological Surgery, Iwate 
Prefectural Central Hospital; Department of Gastroentero-
logical Surgery, Faculty of Medicine, Kagawa University; 
Department of Surgery, Teikyo University Chiba Medical 
Center; Department of Gastrointestinal and Pediatric Sur-
gery, Tokyo Medical University; Department of Surgery, 
The Jikei University School of Medicine; Department of 
Surgery, Saitama National Hospital; Department of Surgery, 
Nakagami Hospital; Department of Gastrointestinal Surgery, 
Japanese Red Cross Nagoya First Hospital; Department of 
Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, 
Nippon Medical School; Department of Surgery, Hachioji 
Digestive Disease Hospital; Department of Gastroenterolog-
ical Surgery, Hirosaki University Graduate School of Medi-
cine; Department of Gastroenterological Surgery, Hiroshima 
City Hiroshima Citizens Hospital; Department of Gastroen-
terological Surgery I, Hokkaido University Graduate School 
of Medicine and Department of Gastroenterological Surgery 
II, Hokkaido University Graduate School of Medicine
References
 1. Gerry JM, Poultsides GA. Surgical management of pancreatic 
cysts: a shifting paradigm toward selective resection. Dig Dis Sci. 
2017;62:1816–26.
 2. Winner M, Epelboym I, Remotti H, Lee JL, Schrope BA, Chabot 
JA, et al. Predictors of recurrence in intraductal papillary muci-
nous neoplasm: experience with 183 pancreatic resections. J Gas-
trointest Surg. 2013;17:1618–26.
 3. Mandai K, Uno K, Yasuda K. Pancreatic ductal adenocarcinoma 
concomitant with intraductal papillary mucinous neoplasm: a 
report of 8 cases. Clin J Gastroenterol. 2013;6:248–54.
 4. Tanno S, Nakano Y, Sugiyama Y, Nakamura K, Sasajima J, Koi-
zumi K, et al. Incidence of synchronous and metachronous pan-
creatic carcinoma in 168 patients with branch duct intraductal 
papillary mucinous neoplasm. Pancreatology. 2010;10:173–8.
 5. Ohtsuka T, Kono H, Tanabe R, Nagayoshi Y, Mori Y, Sadakari 
Y, et al. Follow-up study after resection of intraductal papillary 
mucinous neoplasm of the pancreas; special references to the 
multifocal lesions and development of ductal carcinoma in the 
remnant pancreas. Am J Surg. 2012;204:44–8.
 6. Del Chiaro M, Verbeke C, Salvia R, Klöppel G, Werner J, McKay 
C, et al. European experts consensus statement on cystic tumors 
of the pancreas. Dig Liver Dis. 2013;45:703–11.
 7. Vege SS, Ziring B, Jain R, Moayyedi P. American gastroentero-
logical association institute guideline on the diagnosis and man-
agement of asymptomatic neoplastic pancreatic cysts. Gastroen-
terology. 2015;148:819–22.
 8. Tanaka M, Fernández-del Castillo C, Adsay V, Chari S, Falconi 
M, Jang JY, et al. International consensus guidelines 2012 for the 
management of IPMN and MCN of the pancreas. Pancreatology. 
2012;12:183–97.
 9. Tanaka M, Fernández-Del Castillo C, Kamisawa T, Jang JY, Levy 
P, Ohtsuka T, et al. Revisions of international consensus Fukuoka 
guidelines for the management of IPMN of the pancreas. Pancrea-
tology. 2017;17:738–53.
 10. He J, Cameron JL, Ahuja N, Makary MA, Hirose K, Choti MA, 
et al. Is it necessary to follow patients after resection of a benign 
pancreatic intraductal papillary mucinous neoplasm? J Am Coll 
Surg. 2013;216:657–65.
 11. Kang MJ, Jang JY, Lee KB, Chang YR, Kwon W, Kim SW. 
Long-term prospective cohort study of patients undergoing pan-
createctomy for intraductal papillary mucinous neoplasm of the 
pancreas: implications for postoperative surveillance. Ann Surg. 
2014;260:356–63.
 12. Moriya T, Traverso W. Fate of the pancreatic remnant after resec-
tion for an intraductal papillary mucinous neoplasm: a longitudi-
nal level II cohort study. Arch Surg. 2012;147:528–34.
 13. Tamura K, Ohtsuka T, Ideno N, Aso T, Shindo K, Aishima S, et al. 
Treatment strategy for main duct intraductal papillary mucinous 
neoplasms of the pancreas based on the assessment of recurrence 
in the remnant pancreas after resection: a retrospective review. 
Ann Surg. 2014;259:360–8.
 14. Hirono S, Shimizu Y, Ohtsuka T, Kin T, Hara K, Kanno A, et al. 
Recurrence patterns after surgical resection of intraductal papil-
lary mucinous neoplasm (IPMN) of the pancreas; a multicenter, 
retrospective study of 1074 IPMN patients by the Japan Pancreas 
Society. J Gastroenterol. 2020;55:86–99.
 15. Hashimoto D, Chikamoto A, Taki K, Arima K, Yamashita Y, 
Ohmuraya M, et al. Residual total pancreatectomy: short- and 
long-term outcomes. Pancreatology. 2016;16:646–51.
 16. Miyazaki M, Yoshitomi H, Shimizu H, Ohtsuka M, Yoshidome H, 
Furukawa K, et al. Repeat pancreatectomy for pancreatic ductal 
cancer recurrence in the remnant pancreas after initial pancrea-
tectomy: Is it worthwhile? Surgery. 2014;155:58–66.
 17. Strobel O, Hartwig W, Hackert T, Hinz U, Berens V, Grenacher 
L, et al. Re-resection for isolated local recurrence of pancreatic 
cancer is feasible, safe, and associated with encouraging survival. 
Ann Surg Oncol. 2013;20:964–72.
 18. Hirono S, Kawai M, Okada K, Miyazawa M, Shimizu A, Kitahata 
Y, et al. Long-term surveillance is necessary after operative resec-
tion for intraductal papillary mucinous neoplasm of the pancreas. 
Surgery. 2016;160:306–17.
 19. Blackham AU, Doepker MP, Centeno BA, Springett G, Pimiento 
JM, Malafa M, et al. Patterns of recurrence and long-term out-
comes in patients who underwent pancreatectomy for intraductal 
papillary mucinous neoplasms with high grade dysplasia: impli-
cations for surveillance and future management guidelines. HPB 
(Oxford). 2017;19:603–10.
 20. Yogi T, Hijioka S, Imaoka H, Mizuno N, Hara K, Tajika M, et al. 
Risk factors for postoperative recurrence of intraductal papillary 
mucinous neoplasms of the pancreas based on a long-term follow-
up study: proposals for follow-up strategies. J Hepatobiliary Pan-
creat Sci. 2015;22:757–65.
 21. Al Efishat M, Attiyeh MA, Eaton AA, Gönen M, Basturk O, Klim-
stra D, et al. Progression patterns in the remnant pancreas after 
resection of non-invasive or micro-invasive intraductal papillary 
mucinous neoplasms (IPMN). Ann Surg Oncol. 2018;25:1752–9.
 22. Dhar VK, Merchant NB, Patel SH, Edwards MJ, Wima K, Imbus 
J, et al. Does surgical margin impact recurrence in noninvasive 
intraductal papillary mucinous neoplasms?: a multi-institutional 
study. Ann Surg. 2018;268:469–78.
 23. Marchegiani G, Mino-Kenudson M, Ferrone CR, Morales-
Oyarvide V, Warshaw AL, Lillemoe KD, et al. Patterns of recur-
rence after resection of ipmn: who, when, and how? Ann Surg. 
2015;262:1108–14.
 24. Miyasaka Y, Ohtsuka T, Tamura K, Mori Y, Shindo K, Yam-
ada D, et al. Predictive factors for the metachronous develop-
ment of high-risk lesions in the remnant pancreas after partial 
1680 Surgery Today (2020) 50:1672–1680
1 3
pancreatectomy for intraductal papillary mucinous neoplasm. Ann 
Surg. 2016;263:1180–7.
 25. Pea A, Yu J, Rezaee N, Luchini C, He J, Dal Molin M, et al. 
Targeted DNA sequencing reveals patterns of local progression 
in the pancreatic remnant following resection of intraductal pap-
illary mucinous neoplasm (IPMN) of the pancreas. Ann Surg. 
2017;266:133–41.
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
